# \[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2\].

> PubMed lists PMID 16550880 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, Review, with publication-date metadata of 2006-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16550880-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16550880-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-16550880-exenatide-v1.json
- Content SHA-256: `52cf0a6823ba6e57cf7fd64a9df1e814c6a986864230b64b37344ce2a8fd6597`

## Claims and source pins

### Headline

\[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2\]. ([`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`](#source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133))

### Summary

PubMed lists PMID 16550880 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, Review, with publication-date metadata of 2006-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`](#source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133))

### Paragraph 1

PubMed lists PMID 16550880 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, Review, with publication-date metadata of 2006-03 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`](#source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`](#source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133))

## Sources

<a id="source-pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133"></a>
- **\[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2\]. · retained source version 1:2018-12-01:current:0e886ad4e133c39052a53c44640f6619f2b765ac7da98bf4fb21ed36b60a9e2a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16550880/) (`pubmed-observation-pmid-16550880-2018-12-01-0e886ad4e133`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "\[Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2\]." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-16550880-exenatide-v1.json SHA-256: 52cf0a6823ba6e57cf7fd64a9df1e814c6a986864230b64b37344ce2a8fd6597.